Nivolumab for Hodgkin Disease
This study is evaluating whether a drug may help treat Hodgkin lymphoma.
See full descriptionAbout the trial for Hodgkin Disease
Treatment Groups
This trial involves 2 different treatments. Nivolumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Nivolumab will improve 2 primary outcomes in patients with Hodgkin Disease. Measurement will happen over the course of 2 years.
Patient Q & A Section
What causes hodgkin disease?
Hodgkin disease may be triggered by an infection in you or by exposures to chemicals that are thought to be carcinogenic or otherwise deleterious to lymphocytes, particularly those that cause DNA damage, or by cigarette smoking. More information on potential risk factors is needed to establish whether risk factors play more important roles than genetics in the development of Hodgkin disease in humans. The most convincing evidence that cigarette smoking increases risk is in children, but the magnitude of the increase is small and is less conclusive for adults. A similar increase in risk is seen in those exposed to benzene, a chemical in cigarette smoke. The same is not seen for those exposed to some kinds of UV radiation.
What are the signs of hodgkin disease?
ix) a palpable mass anywhere, if a lesion, ix) the presence of lymphadenopathy if lymphadenopathy, ix) an adenopathy if adenopathy, and ix) a lymphadenopathy if lymphadenopathy. ix) palpable mass if a lesion, ix) the presence of lymphadenopathy if lymphadenopathy, ix) the presence of an adenopathy if an adenopathy, and ix) a lymphadenopathy if an adenopathy.
Can hodgkin disease be cured?
The overall 5-year survival for patients with Stage IV HD was 36%. The 5-year OS for patients treated with a standard therapy protocol was 35%. Although this was not statistically significant in univariate analysis, the results of this retrospective study do not support the use of current standard therapy protocols to treat this disease.
What are common treatments for hodgkin disease?
Treatment options for Hodgkin's disease are dependent on the extent, type, and location of the disease in the body. Patients receiving corticotherapy have poorer 5-year overall and progression-free survival compared to patients without corticotherapy. There is no clear evidence that cranially administered radiotherapy improves survival compared to the risks and side-effect profile of corticotherapy. Radiation therapy is associated with a markedly low incidence of severe acute (and often serious) GI toxicity when used as a palliative treatment option for patients with high-risk disease in the neck or mediastinum. Chemotherapy can be used alone or in combination with chemotherapy or radiotherapy.
How many people get hodgkin disease a year in the United States?
Around 1,200,000 people will be diagnosed with Hodgkin disease each year, making it the sixth-most common cancer in American men. Of new cases of Hodgkin disease 10,100 people succumb to the disease each year, making it the most common cause of cancer-related death among young adults in the United States.
What is the average age someone gets hodgkin disease?
The average age a person gets diagnosed with Hodgkin disease is 39 years, but the age of diagnosis varies depending on the location and racial ancestry among other factors.
How quickly does hodgkin disease spread?
If a patient has a history of lymph node cancer or the development of a second malignancy within the past 10 years, prompt examination to look for involvement of the primary site should be undertaken. If a patient has a new noncontiguous primary neoplasm with symptoms of a mass or extracutaneous nodules, then a biopsy from the site of the new neoplasm should be conducted. Patients with symptomatic LDH-HOD seem to have an acceptable 3 year overall survival of 96%.
Who should consider clinical trials for hodgkin disease?
All patients with HD should consider enrolling in clinical trials. Patients who have a prolonged course of therapy with high-dose CHOP chemotherapy are particularly likely to benefit; this group might also be eligible for trials involving a new and nontoxic induction regimen.
What is the survival rate for hodgkin disease?
Patients with HD have variable survival rates according to racial, age, and T stage. There is also variation in the use of chemotherapy according to the characteristics of the patient, including the presence of extrapleural disease and the extent of disease at the time of diagnosis.
How serious can hodgkin disease be?
Despite several years of treatment, about half the people with metastatic non-bulky disease had a sustained response to treatment. The majority of patients had minimal symptoms for some years after diagnosis. Most patients were satisfied or very satisfied with their treatment. [There is a range of hodgkins disease treatments, including surgery, chemotherapy, and radiotherapy; about 10% of people have no or very little symptoms or complications, according to a survey in the Netherlands, 2013. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC39073326/fulltext.htm)].
Have there been any new discoveries for treating hodgkin disease?
There have not been any dramatic advancements for treating hodgkin disease compared to today. Treatment is still a complex and expensive process so even if there were a new way of treating this disease, only a few people would probably benefit from the treatment. Current treatment is still very effective and affordable so it’s crucial for doctors to work hard to continue studying this disease.